A phase IV study to evaluate the primary and booster immune responses of UK preterm infants receiving licensed DTaP/Hib/IPV and meningococcal C conjugate vaccine and incorporating a randomisation study of a 3 dose accelerated versus a 2 dose and a 3 dose extended schedule of pneumococcal conjugate vaccine for primary immunisation
Latest Information Update: 22 Jul 2019
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine; Hib-meningococcal vaccine group C conjugate; Meningococcal vaccine group C conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms PUNS
- 21 Jul 2019 Status changed from active, no longer recruiting to completed.
- 20 Aug 2013 New source identified and integrated: European Clinical Trials Database record.
- 24 May 2013 Accrual to date is 105% according to United Kingdom Clinical Research Network.